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Availability, prices and affordability of 
essential medicines in Haiti
Background Haiti is the poorest country in the Western Hemisphere 
and faces numerous challenges, including inadequate medication 
access for its residents. The objective of this study was to determine 
the availability, prices, and affordability of essential medicines in Hai-
ti and compare these findings to other countries.
Methods We conducted a cross–sectional nationwide survey in 2011 
of availability and consumer prices of 60 essential medicines in Hai-
ti using a standardized methodology developed by the World Health 
Organization and Health Action International. The survey was con-
ducted in 163 medicine outlets in four health care sectors (public, 
retail, nonprofit and mixed sectors). Medicine prices were expressed 
as ratios relative to the International Reference Price. Affordability 
was calculated by comparing the costs of treatment for common con-
ditions with the salary of the lowest paid government worker and 
was compared to available data from four Latin American countries.
Results For generic medicines, the availability in public, retail, non-
profit and mixed sectors was 20%, 37%, 24% and 23% of medica-
tions, respectively. Most of the available medicines were priced high-
er than the International Reference Price. The lowest paid government 
worker would need 2.5 days’ wages to treat an adult respiratory in-
fection with generic medicines from the public sector. For treatment 
of common conditions with originator brands (OB) purchased from 
a retail pharmacy, costs were between 1.4 (anaerobic bacterial infec-
tion) and 13.7 (hyperlipidemia) days’ wages, respectively. Treatment 
of pediatric bacterial infections with the OB of ceftriaxone from a re-
tail pharmacy would cost 24.6 days’ wages. Prices in Bolivia, Colom-
bia, Mexico and Nicaragua were frequently lower for comparable 
medications.
Conclusions The availability of essential medicines was low and 
prices varied widely across all four sectors. Over 75% of Haitians live 
on less than US$ 2.00 /day; therefore, most medication regimens are 
largely unaffordable. Inclusion of essential medications on the na-
tional formulary and working with organizations responsible for im-
porting medications into Haiti, particularly drug donation agencies, 
are important first steps to increasing medication access.
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ply, is the central agency for the provision of essential med-
icines and supplies in Haiti. Under PAHO/WHO technical 
and managerial leadership since 1992, PROMESS is the 
main storage and distribution center that coordinates the 
efforts and contributions of international partners to im-
prove access to essential medicines [18].
The objective of this study was to measure the availability, 
prices, and affordability of essential medicines in Haiti and 
compare these findings to other countries. These data pro-
vide evidence to guide policy ensuring that all Haitians have 
access to and the ability to afford life–saving medications.
METHODS
Study design and site
The cross–sectional survey of medicine availability and pric-
es was conducted according to the WHO and Health Action 
International (WHO/HAI) methodology to facilitate com-
parisons with other countries. The survey of was conducted 
nationwide, in all ten regions of Haiti, in August 2011.
Selection of medicine outlets
Sampling of medicine outlets was conducted according to 
the WHO/HAI methodology, which has been shown 
through a recent validation study to yield a nationally rep-
resentative sample [19]. Lists of health facilities and retail 
pharmacies were provided by the Ministry of Health and 
the Regional Health Departments for each survey region. 
Within each region, the main public hospital was selected. 
Then, four to five medicine dispensing outlets (eg, hospital 
out–patient medicine outlets, dispensaries) were selected 
from those within a 4–hour drive from the main hospital 
in each sector. Data on 59 medicines and one device was 
collected from 54 public, 35 private (retail), 39 nonprofit, 
and 35 mixed sector medicine outlets. Mixed sector con-
tains outlets that are managed in a collaborative partner-
ship between the Ministry of Health and a nonprofit group.
Selection of medicines
The WHO/HAI methodology specifies a core list of 14 
global medicines and 16 regional medicines commonly 
used in the treatment of a range of chronic and acute con-
ditions [19]. To facilitate international comparisons, the 
methodology also includes the specific dosage form and 
strength to be surveyed for each medicine.
In Haiti, all medicines from the WHO/HAI core lists were 
included in the survey [20]. An additional 28 medicines 
and 1 device identified as high priority essential medicines 
for children by the WHO Better Medicines for Children 
project were also included in the survey [21]. Enalapril 
5mg, from the Haiti NEML [22] was also added to the sur-
The World Health Organization (WHO) Essential Medi-
cines List (EML) serves as a model for public supply and 
reimbursement of medicines. The list was first drafted in 
1977 and expanded in 2007 to include essential medicines 
for children. The list highlights the most critical medicines 
for adult and pediatric patients [1]. Biannual revisions of 
the list take into account disease prevalence and the safety 
and efficacy of medicines, and since 2002, have adhered to 
rigorous standards of evidence [2]. The essential medicines 
concept may also be used to develop evidence–based clin-
ical guidelines and a national medicines policy.
Data from national surveys have shown that access to es-
sential medicines, particularly for children, is generally 
poor and prices can be unaffordable [3–8]. The reasons for 
the lack of access to essential medicines can include the 
absence of essential medicines policies, no regulated med-
icines, fragile supply systems, or out–of–pocket payments 
which make the medicines unaffordable. The EML can be 
adopted by countries according to their priority health care 
needs. National essential medicines lists (NEML) can be an 
important first step toward ensuring access to medicines 
since they can guide procurement, local licensing and man-
ufacturing, and the quality use of essential medicines [9].
Haiti is the poorest country in the Western Hemisphere 
and, after the 2010 earthquake, has been facing significant 
challenges in meeting the health care needs of its residents 
[10]. The availability of essential medicines to address some 
of these needs is unknown. Haiti is a low income country 
with a GDP of US$ 726 per capita in 2011 [11]. About 54% 
of the population lives on less than US$ 1/day, and 78% 
live on less than US$ 2/day [12]. In 2010, Haitian life ex-
pectancy at birth was 60 years for males and 63 years for 
females compared with a regional average of 73 and 79 
years for males and females, respectively [13]. In Haiti in 
2011, mortality among children under 5 was 70 per 1000 
compared to the rate of 19 per 1000 live births in the WHO 
Americas region [14]. The Haiti maternal mortality rate in 
2010 was 350 deaths per 100 000 live births compared to 
a regional rate of 63 per 100 000 live births [13].
The poor health care conditions in Haiti are related to many 
factors including inadequate health care infrastructure, lack 
of health care providers and lack of health education. How-
ever, one of the least studied areas of health care in Haiti 
has been access to essential medicines. Many of the exist-
ing health problems facing Haiti can be treated or prevent-
ed by the use of essential medicines. Tuberculosis remains 
endemic and is a significant cause of mortality [15]. Ma-
laria continues to remain a deadly problem in Haiti with a 
prevalence rate of 2–3% as of 2010 [16]. In 2010, diarrhea 
was found to be the fifth leading cause of death for Haitian 
children under 5, accounting for 7% of deaths [17]. 
PROMESS, the Program for Essential Medicines and Sup-
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vey to be evaluated alongside the Enalapril 10 mg from the 
regional core list. The list of survey medicines is provided 
in Online Supplementary Document, Table w1.
For each medicine in the survey, data were collected for the 
originator brand, highest priced generic equivalent, and 
lowest priced generic at each facility.
Data collection
The survey team consisted of 14 data collectors; 5 student 
pharmacists from University of California, San Francisco 
– School of Pharmacy, 6 students from State University of 
Haiti – Faculty of Medicine and Pharmacy (UEH–FMP), 
and 1 physician, 1 pharmacist, and 1 alumni from UEH. 
All survey personnel received training in survey methodol-
ogy and data collection procedures prior to data collection. 
As part of the training workshop, two data collection pilot 
tests were conducted at retail medicine outlets which did 
not form part of the survey sample.
Data collection took place between August 4 and August 
16, 2011. Supervisors checked all forms at the end of each 
day of data collection, and validated the data collection 
process by collecting data at 20% of the medicine outlets 
and comparing their results with those of the data collec-
tors. Discrepancies were rare between data collectors and 
supervisors and were corrected when found. When at least 
50% of the targeted medicines in any given medicine out-
let were not found, an attempt was made to survey an ad-
ditional outlet. All outlets were included in the analysis.
Data analysis
The availability of individual medicines is calculated as the 
percentage (%) of outlets where the medicine was found. 
Mean (average) availability was calculated for originator 
brands and the lowest priced generics for the basket of all 
60 medications within each sector.
Data from Haiti were compared to data from Nicaragua, 
Mexico, Colombia, and Bolivia as these were the countries 
in the Americas region with available, recent essential med-
icines surveys. To facilitate cross–country comparisons, 
medicine patient prices obtained during the survey are ex-
pressed as ratios relative to a standard set of international 
reference prices: Median Price Ration (MPR) = Median Lo-
cal Unit Price / International Reference Unit Price.
Thus, a median price ratio of 2 would mean that the local 
medicine price is twice that of the International Reference 
Price. Median price ratios were calculated only for medi-
cines with price data from at least 4 medicine outlets. The 
exchange rate used to calculate median price ratios was 1 
US$ = 39.6862 Gourdes; the commercial “buy” rate on the 
first day of data collection [23].
The 2010 International Drug Price Indicator Guide was 
used to determine the reference prices [24]. These refer-
ence prices are the medians of recent procurement prices 
offered by for–profit and not–for–profit suppliers to inter-
national not–for–profit agencies for generic products.
The affordability of treating seven common conditions for 
adults and two common conditions for children was as-
sessed by comparing the total cost of the lowest priced ge-
neric medicines prescribed at a standard dose to the daily 
wage of the lowest paid unskilled government worker of 
US$ 5.04 [25]. For acute conditions, treatment duration 
was defined as a full course of therapy, while for chronic 
diseases, the affordability of a 30 days’ supply of medicines 
was determined.
This study was reviewed by University of California, San 
Francisco, Committee on Human Research, and declared 
not to fit the definition of human research (exempt), refer-
ence number 11–06271.
RESULTS
Availability
Availability of medicines in the public, private, nonprofit and 
mixed sectors. Table 1 shows that the availability of lowest 
priced generic essential medicines varied by medicine, but 
was low across all sectors of health care. The mean avail-
ability of lowest priced generic medicines in the public, re-
tail, nonprofit, and mixed sectors was 20%, 37%, 24% and 
23% of medications, respectively. Originator brand avail-
ability was even lower across all sectors: public (2%), retail 
(5%), nonprofit (2%), and mixed (1.5%). Highest priced 
generics were found only in the private sector. The vast ma-
jority of outlets in all other sectors carried only one generic 
product per medicine. Therefore, there was insufficient data 
to make any comparisons to highest priced generics.
International comparisons of private sector availability. Inter-
national comparison of the availability of nine originator 
brands in the private sectors was possible across Haiti, Ni-
caragua, Mexico, Colombia, and Bolivia. Compared to oth-
er countries, Haiti had the lowest originator product avail-
ability for atenolol (11% of outlets), ciprofloxacin (6%), 
and diclofenac (34%). The overall availability of the nine 
originator products that were surveyed across all countries 
was 13% of medicines in Haiti, compared to 19%, 47%, 
23%, and 4% in Nicaragua, Mexico, Colombia, and Boliv-
ia, respectively.
Table 2 shows the country comparisons of the availability 
of 12 lowest priced generic medicines in the private sector 
that were surveyed in all 5 countries. The average availabil-
ity of lowest priced generics in Haiti was 73% for these 12 
medications, compared to 84% in Nicaragua, 48% in Mex-
ico, 79% in Colombia, and 71% in Bolivia.
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Consumer prices in public, private, nonprofit, and mixed sec-
tors. Across all four sectors, the medicines in Haiti were sold 
at higher prices than the international reference price. Table 
3 shows that consumer prices in Haiti were closest to the 
international reference price for originator brands sold in 
Chahal et al.
Table 1. Availability of lowest priced generic formulation of each medication
Percent (%) of outlets where medicine was found
Medicine name Public sector 
(n = 54)
Retail sector
(n = 35)
Nonprofit 
sector
(n = 39)
Mixed sector
(n = 35)
Amitriptyline 1.9 11.4 7.7 2.9
Amlodipine 5.6 68.6 28.2 5.7
Amoxicillin 63 97.1 89.7 57.1
Amoxicillin Dispersible Tab 14.8 5.7 23.1 8.6
Amoxicillin suspension 50.0 51.4 46.2 48.6
Amoxicillin Suspension 125 mg/5 ml 68.5 97.1 56.4 80
Amoxicillin/Clavulanic Dispersible tab 0 2.9 0 0
Amoxicillin/Clavulanic Suspension 0 8.6 0 2.9
Atenolol 22.2 74.3 38.5 42.9
Atorvastatin 0 14.3 0 0
Azithromycin 9.3 65.7 15.4 11.4
Beclometasone Inhaler (100 μg) 0 0 2.6 0
Beclometasone inhaler (250 μcg) 0 2.9 0 0
Benzyl Penicillin Injection 3.7 0 2.6 5.7
Captopril 29.6 57.1 30.8 31.4
Carbamazepine Chewable Tablet 3.7 0 2.6 0
Carbamazepine Suspension 0 0 0 0
Ceftriaxone injection (1 g/vial) 51.9 71.4 51.3 51.4
Ceftriaxone injection (500 mg/vial) 7.4 2.9 12.8 2.9
Chloramphenicol Injection (1g/vial) 11.1 22.9 15.4 5.7
Chloroquine 55.6 77.1 71.8 62.9
Ciprofloxacin 57.4 91.4 76.9 77.1
Clonazepam 0 5.7 0 0
Clotrimazole topical cream 14.8 45.7 25.6 11.4
co–trimoxazole Dispersible Tablet 9.3 2.9 15.4 20
Co–trimoxazole suspension 51.9 62.9 64.1 71.4
Diazepam 25.9 45.7 30.8 40
Diazepam Rectal Solution 0 0 0 0
Diclofenac 46.3 85.7 43.6 42.9
Enalapril 35.2 85.7 41 37.1
Enalapril (5mg) 11.1 82.9 15.4 25.7
Ferrous Salt Suspension 3.7 5.7 0 8.6
Fluoxetine 5.6 14.3 0 2.9
Furosemide 38.9 77.1 48.7 60
Gentamycin Injection 5.6 0 2.6 0
Glibenclamide 29.6 80 41 54.3
Hydrochlorothiazide 38.9 65.7 35.9 34.3
Ibuprofen (200 mg) 24.1 31.4 56.4 40
Ibuprofen (400 mg) 66.7 82.9 61.5 80
Isoniazid 0 0 0 0
Metformin 20.4 62.9 15.4 8.6
Metronidazole 46.3 88.6 59 48.6
Morphine Dispersible Tablet 0 0 5.1 0
Morphine Oral Solution 0 0 0 0
Omeprazole 40.7 97.1 46.2 34.3
Oral Rehydration Solution (1 L) 48.1 45.7 69.2 80
Oral Rehydration Solution (500 ml) 0 0 0 5.7
Paracetamol suspension (120 mg/5 ml or 125 mg/5 ml) 48.1 77.1 51.3 60
Phenobarbital Injection 0 0 0 0
Phenobarbital Oral Liquid 3.7 8.6 0 0
Phenytoin 9.3 17.1 25.6 11.4
Phenytoin Chewable Tablet 0 0 0 0
Phenytoin Suspension 0 0 0 0
Procaine Penicillin Injection 3.7 8.6 0 2.9
Ranitidine 24.1 80.0 33.3 51.4
Salbutamol inhaler 25.9 85.7 35.9 37.1
Simvastatin 1.9 57.1 2.6 0
Spacer (for Inhalers) 0 0 2.6 0
Vitamin A 25.9 8.6 23.1 14.3
Zinc Dispersible Tablet 7.4 2.9 5.1 11.4
the public sector. Originator brands prices in the private 
sector in Haiti were 35 times the international reference 
price.
Table w2 in Online Supplementary Document shows me-
dian price ratios for selected lowest priced generic medica-
tions, by sector.
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Table 2. Availability and median price ratios (MPR) of 12 essential lowest priced generic medications in Haiti compared to 4 neigh-
boring countries
Haiti Nicaragua Mexico Colombia Bolivia
Medication (strength)
Avail-
ability 
(%)*
MPR
Avail-
ability
(%)
MPR
Avail-
ability
(%)
MPR
Avail-
ability
(%)
MPR
Avail-
ability
(%)
MPR
Amitriptyline 25 mg 11.4 13.3 51.6 11.2 0 N/A 93.2 6.4 50 8.3
Amoxicillin 500 mg 97.1 4.3 100 2.2 53.3 4.3 96.6 2.5 100 2.3
Atenolol 50 mg 74.3 15.9 61.3 4 6.7 N/A 11.9 10.1 73.3 6.15
Captopril 25 mg 57.1 10.5 93.5 4 86.7 5.5 96.6 1.5 0 N/A
Ceftriaxone 1 g/vial 71.4 5.5 90.3 3.6 73.3 6.6 49.2 3 93.3 1.1
Ciprofloxacin 500 mg 91.4 5.1 100 8 80 12.7 100 4.8 96.7 4.4
Co–trimoxazole 8 + 40 mg/ml 62.9 4.5 83.9 4.2 80 4.5 86.4 4 86.7 4
Diclofenac 50 mg 85.7 25.2 96.8 11.3 6.7 N/A 96.6 7.9 100 7.9
Glibenclamide 5 mg 80 20.4 83.9 10.4 46.7 5.2 91.5 7.3 90 13
Omeprazole 20 mg 97.1 4.2 96.8 6.3 80 9.3 94.9 2.2 96.7 3.3
Salbutamol 100 μg/dose 85.7 2.3 71 3 53.3 2.1 96.6 1.4 60 2.4
Simvastatin 20 mg 57.1 N/A 83.9 N/A 6.7 N/A 35.6 N/A 6.7 N/A
N/A – Not Available or Not Applicable
*Percent (%) of retail outlets with medication.
Medicines were not priced consistently in relation to their 
international reference price. In the public sector, half of 
the lowest priced generic medicines were priced at 3.4 (25th 
percentile) to 9.0 (75th percentile) times their international 
reference price. In the retail sector, half of the originator 
brand medicines were priced at 11.2 (25th percentile) to 
47.4 (75th percentile) times their international reference 
price and half of the lowest priced generic medicines were 
priced at 4.4 (25th percentile) to 14.3 (75th percentile) times 
their international reference price. In the nonprofit sector, 
half of the lowest priced generic medicines were priced at 
3.3 (25th percentile) to 10.2 (75th percentile) times their in-
ternational reference price and finally in the mixed sector, 
half of the lowest priced generic medicines were priced at 
3.1 (25th percentile) to 6.9 (75th days’ percentile) times their 
international reference price.
International comparisons of private sector prices. As shown 
in Table 2, most of the 12 lowest priced generic medica-
tions were sold at higher prices in Haiti compared to Nica-
ragua, Mexico, Colombia, and Bolivia. On average, these 
medications were sold in Haiti at 10 times the internation-
al reference price, compared to seven times the interna-
tional reference price in Nicaragua, 6 times the interna-
tional reference price in Mexico and Colombia, and 5 times 
the international reference price in Bolivia.
Affordability
Affordability of medicines to treat common conditions. Table 4 
shows that most of the lowest priced generics needed to 
treat 10 common uncomplicated conditions cost less than 
a day’s wage in the public sector. Treatments costing over 
a day’s wage include diabetes with metformin 850 mg (1.5 
days’ wages) and hypertension with captopril 25 mg (1.2 
days’ wages). However, given the low availability of medi-
cines in the public sector, many patients must purchase 
medicines from the private sector.
Table 4 shows that in the private sector, the affordability of 
the lowest priced generics varies from 0.2 to 5.3 days' wages. 
Treatments that cost more than one day’s wage include dia-
betes with metformin 850 mg (1.7 days’ wage), hypertension 
with captopril 25 mg (1.5 days’ wage), and hyperlipidemia 
with simvastatin 20 mg (2.1 days’ wage). Treatment of respi-
ratory infection with ceftriaxone 1g/vial cost 5.3 days’ wage. 
The most affordable standard treatments were those for treat-
ing chronic conditions such as asthma with salbutamol 
100mcg (0.8 days’ wage) and diabetes with glibenclamide 5 
mg (0.8 day’s wage). The most affordable standard treat-
ments were those for treating acute conditions like respira-
tory infection with ciprofloxacin 500 mg and amoxicillin 
500 mg (0.4 and 0.5 days’ wage, respectively).
When originator brands are prescribed and dispensed in 
the private sector, several treatments cost well over one 
day’s wage. Treatment of respiratory infection with ceftri-
axone 500 mg and ceftriaxone 1g costs 24.6 and 28.0 days’ 
wages, respectively, while treating arthritis with diclofenac 
50 mg costs 9.0 days’ wages.
We calculated the number of days’ wages required to treat 
a family with 3 chronic conditions. To treat a mother’s dia-
betes with 30 days of metformin, 1.5 days’ wages are re-
quired. In addition, 1.2 days’ wages are required to treat 
the father’s hypertension with captopril for 30 days’ and 
Table 3. Median price ratios (MPR) of originator and lowest 
priced generic medicines by sector
Type of medicine
Sector Originator Brand Lowest Priced Generic
Public 1.6 4.8
Private 35 7
Nonprofit N/A 4.3
Mixed N/A 4.0
MPR – Median Price Ratio = median local unit price/international 
reference unit price, N/A = insufficient data available for calcula-
tion.
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0.7 days’ wages are required to treat the child’s asthma. 
Thus, 3.4 days’ wages, or US$ 17.14 per month, are re-
quired for the family.
International comparisons of private sector consumer prices of 
medicines to treat common conditions. Data were available to 
compare the median price ratios of treatment for adult re-
spiratory infection with ceftriaxone 1 g/vial injection pur-
chased in the private sector. Figure 1 shows that with either 
generic or originator brand formulations, the cost of the 
treatment in Haiti significantly exceeds that of the compar-
ator countries.
DISCUSSION
The availability of essential medicines for adults and chil-
dren is poor across all sectors of health care in Haiti. Ge-
neric equivalents were the predominant product type avail-
Table 4. Number of days’ wages needed for the lowest paid Haitian government worker to purchase standard treatments for adults and 
children in Haiti
For Adults (daily wage: 200 HTG (US$ 5.04/day)
Disease condition and ‘standard’ treatment Day’s wages to pay for treatment
Condition, drug name, strength, 
dosage form
Treatment schedule
Lowest 
priced 
generic 
– public 
sector
Lowest 
priced 
generic 
– private 
sector
Lowest 
priced 
generic 
– nonprofit 
sector
Lowest 
priced 
generic 
– mixed 
sector
Asthma
Salbutamol 100 μg/dose inhaler 1 inhaler of 200 doses 0.7 0.8 0.6 08
Diabetes
Glibenclamide 5 mg cap/tab 1 cap/tab ×2 × 30 days = 60 0.8 0.8 0.5 0.6
Metformin 850 mg cap/tab 1 cap/tab ×2 × 30 days  = 60 1.5 1.7 n/a N/A
Hypertension
Atenolol 50 mg cap/tab 1 cap/tab ×30 days  = 30 0.4 0.9 0.6 0.8
Captopril 25 mg cap/tab 1 cap/tab ×2 30 days  = 60 1.2 1.5 1.5 0.9
Amlodipine 5 mg cap/tab 1 cap/tab ×30 days  = 30 N/A 0.8 0.5 N/A
Hyperlipidemia
Simvastatin 20 mg cap/tab 1 cap/tab ×30 days  = 30 N/A 2.1 N/A N/A
Atorvastatin 10 mg cap/tab 1 cap/tab ×30 days  = 30 N/A 2.6 N/A N/A
Bacterial infection
Ciprofloxacin 500 mg cap/tab 1 cap/tab ×2 for 7 days  = 14 0.4 0.4 0.4 0.4
Amoxicillin 500 mg cap/tab 1 cap/tab ×3 for 7 days  = 21 0.3 0.5 0.4 0.4
Ceftriaxone 1 g/vial injection 1 vial ×7 days  = 7 vials 2.5 5.3 4.2 3.5
Anxiety
Diazepam 5 mg cap/tab 1 cap/tab ×7 days = 7 0.2 0.2 0.1 0.1
Arthritis
Diclofenac 50 mg cap/tab 1 cap/tab ×2 × 30 days  = 60 0.6 1.3 0.6 0.5
Ulcer
Omeprazole 20 mg cap/tab 1 cap/tab ×30 days  = 30 0.8 0.8 0.7 0.5
Ranitidine 150 mg cap/tab 1 cap/tab ×2 × 30 days  = 60 0.9 1.4 0.9 0.8
For Children
Bacterial infection
Amoxicillin Suspension  
125 mg/5 mL
Child up to 10 years: 125 mg  
( = 5 ml) × 3 × 7 days = 105 ml
0.3 0.3 0.3 0.3
Amoxicillin Suspension 250 mg/5 
mL
Child over 10 years: 250 mg  
( = 5 ml) × 3 × 7 days = 105 ml
0.3 0.4 0.3 0.3
Co–trimoxazole 8 + 40 mg/ml 
suspension
5 ml twice a day for 7 days = 70 ml 0.2 0.3 0.2 0.4
Pain/inflammation
Paracetamol 24 mg/ml suspension 5-year-old child: 15 mg/kg ×20 kg 
×4 × 3 days= 3600 mg ( = 150 mL)*
0.5 0.6 0.4 0.5
*Weight of average 5-year-old old child = 20 kg (Centers for Disease Control and Prevention, United States)
able in all outlets, across all sectors. Prices varied widely 
across sectors and medicines for the treatment of common 
conditions are not affordable for the majority of Haitians. 
Figure 1. Median price ratios for treatment for adult respiratory 
infection with ceftriaxone 1 g/vial injection purchased in the 
private sector in five countries.
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These findings are consistent with studies of the availabil-
ity and affordability of essential medicines in other coun-
tries [4,26–29].
A significant number of medicines were not found in any 
of the outlets – 16 medicines in the public sector, 13 in the 
retail sector, 15 in the nonprofit sector, and 19 in the mixed 
sector. Ten medicines were not found in any outlet in the 
public, nonprofit, and the mixed sectors. Eight of these 10 
medications are used for management of pediatric condi-
tions. Among the medicines that were lacking for pediatric 
use were phenytoin suspension and diazepam rectal solu-
tion for treatment of epileptic disorders, oral rehydration 
solution packets and amoxicillin/clavulanic acid dispersible 
tablets for bacterial infections.
Morphine formulations were not expected to be available 
at primary or clinic level of care or in retail settings. How-
ever, the surveyed formulations of morphine were also not 
found at secondary level regional hospitals or tertiary level 
hospitals. Although not surveyed, morphine in injection 
form was found only at the tertiary level public and non-
profit hospitals. The observed low availability may be due 
to the regulations placed on importation and/or manufac-
turing of opioid analgesics by the Haitian government [30]. 
Opioid availability and use has also been observed to be 
low after natural disasters [31]. Haiti has one of the lowest 
reported uses of opioid analgesics in Latin America and 
worldwide [30,32]. The low use of opioids for pain control 
may stem from the need for additional medical knowledge 
and biases that may exist for the treatment of pain with 
opioid based medications [30]. Furthermore, a compara-
tive study found that the cost of opioids in developing 
countries was higher than in developed countries, which 
can limit availability and affordability in countries such as 
Haiti [33]. A recent WHO study indicated a strong positive 
correlation between development of a country and ade-
quate access to opioids [30].
The prices of essential medicines in Haiti were consider-
ably higher than the international reference price and there 
was a notable variability in prices across outlets in all health 
care sectors. The variability observed between outlets may 
have been the result of low market competition (as is the 
case outside of the capital city), the absence of price regu-
lations on pharmaceutical products throughout the coun-
try, or differences in procurement and/or variability in price 
mark–ups throughout the distribution chain and in the ar-
eas surveyed. Further investigation of medicine pricing 
components is warranted.
In the public sector, the affordability of lowest priced ge-
nerics was good for most conditions, with standard treat-
ment costing up to one day’s wage. However, low public 
sector availability may force some patients to purchase 
higher priced medicines from the private sector. In the pri-
vate sector, some of the treatments, such as those for dia-
betes, hyperlipidemia, and hypertension, cost close to the 
daily wage of the lowest paid government worker, even 
when lowest priced generics are used. The majority of stan-
dard treatments were much less affordable when originator 
brands were purchased in the private sector.
Most Haitians earn much less than the lowest government 
wage, so even treatments which appear affordable were too 
costly for the poorest segments of the population. Given 
that 54% of the population is living below the internation-
al poverty line of less than US$ 1/day and 78% of the pop-
ulation in Haiti lives on less than US$ 2/day, essential med-
icines are financially out–of–reach for a substantial number 
of people [12].
Although treatment for some acute conditions such as bac-
terial infections may be affordable, the ongoing costs of 
treating chronic illnesses such as diabetes, hypertension, 
and hyperlipidemia may be insurmountable for many pa-
tients in Haiti [4,28]. According to the Pan American 
Health Organization (PAHO) the burden of chronic dis-
eases in Haiti is high; a 2010 study in Port–au–Prince met-
ropolitan area found hypertension prevalence of 48.7% and 
46.5% in men and women, respectively [16]. The 2010 
WHO report on noncommunicable diseases estimated the 
prevalence of overweight and obesity in Haiti at 32%, 
which increases the risks for chronic conditions such as 
cardiovascular diseases and diabetes [34]. The situation is 
further complicated by the observed lower availability of 
medications for treatment of chronic diseases vs acute con-
ditions [26,28]. The monthly cost of long–term manage-
ment of multiple chronic illnesses can exceed several days’ 
wages of the lowest paid government employee. As shown 
in our example of a family of 3 requiring medicines for 
asthma, diabetes, and hypertension, the cost is US$ 17.14 
per month and 54% of the Haitian population lives on US$ 
30 per month. In addition, treatment costs were for medi-
cines only and did not include the costs of consultation and 
diagnostic tests that place additional financial burden on 
patients [35,36].
Similar to adult medications, the availability of child–spe-
cific generic medicines far exceeded that of originator prod-
ucts across all sectors. Even so, most outlets only carried 
3% to 50% of children’s essential medications. This is con-
sistent with a recent study on the availability of children’s 
mediations conducted in 14 African countries, where avail-
ability of medications ranged from 15–75% of outlets, rare-
ly exceeding 50% availability in any given outlet [8].
The affordability of treatments for children is no better than 
the availability. The leading causes of death of children un-
der five in Haiti are diarrheal diseases, respiratory infec-
tions and malnutrition, and the under–five child mortality 
rate in Haiti in 2011 was 70 children per 1000 [14]. Amox-
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icillin suspension is used to manage respiratory infections, 
and was the most common medication available for pedi-
atric bacterial infections. However, the suspension was sold 
at, on average, three times the international reference price. 
Originator brand dispersible zinc tablets were widely avail-
able across sectors (except retail) for the management of di-
arrhea [37]. The cost of the zinc tablets was about 1.5 times 
the international reference price in the public sector, al-
though zinc tablets were available free of charge in the pub-
lic, nonprofit, and mixed sectors. However, oral rehydration 
solution (ORS) was available in only about half of the pub-
lic outlets and in 80% of the mixed sector outlets; and when 
it was found, the ORS sold at 2.4 times the international 
reference price in retail outlets. It is unusual for zinc to be 
available more often than ORS and for it to be sold at a low-
er median price ratio [3,8]. It is possible that the availabil-
ity of zinc in Haiti increased due to campaigns such as the 
one undertaken by UNICEF and its supporting partners in 
response to the cholera outbreak in October 2010 [38].
The comparisons with other Latin American countries sug-
gest that the availability of lowest priced generics in Haiti 
is similar to that of the other countries. However, since 
medications in Haiti are priced higher than other countries, 
the affordability of those medications is much less. Further 
research is needed to identify the reasons for variation be-
tween different countries. Possible reasons include factors 
like size of the markets, capabilities of the national phar-
maceutical manufacturing sector, the effect of taxes, duties, 
and mark–ups at national and local levels, and economic 
indicators. Such information would be useful for policy-
makers and governments in deciding what specific inter-
ventions can be made to make medicines more affordable 
and accessible in each country. Further studies and com-
parisons between high and low–income countries could 
also provide an evidence base for equitable or differential 
pricing strategies by multinational manufacturers, so that 
less wealthy populations can pay the same or less than 
wealthier countries for essential medicines.
We had suspected that the increase in medication dona-
tions after the 2010 earthquake in Haiti may have resulted 
in a sustained influx of essential medicines in Haiti, but this 
was not the case. Immediately after the earthquake, 
PROMESS played a key role in dispersing medicines as 
quickly as possible to where they were needed. However, 
in order for PROMESS to be effective in coordinating do-
nations over the long term, it must have adequate staffing 
by pharmacists and logistics experts, as well as good com-
munication with all donating agencies [39]. Furthermore, 
emergency drug donations are infrequently guided by es-
sential medicines lists [40]. Donations that are not adher-
ent to the WHO Guidelines for Medication Donations [41], 
which include the recommendation that donated medi-
cines be essential medicines, can be more burdensome to 
the health care system than helpful, especially in an emer-
gency situations [37,42–44]. Haiti is a participant in the 
PAHO Strategic Fund created by PAHO in 2000. Through 
the Strategic Fund, Haiti is eligible to receive technical as-
sistance on how to review the supply management system 
and develop a coordinated procurement plan which could 
inform the coordination of donations [45].
The use of the WHO/HAI medicine prices survey allowed 
us to measure prices and availability in a reliable and stan-
dardized way in order to make valid international compar-
isons. A further strength of the methodology is the multiple 
steps taken to ensure data quality [46]. However, our study 
has some limitations. Data on medication availability are 
influenced by market fluctuations and delivery schedules. 
Therefore data on medication availability at a single point 
in time may not reflect average monthly or yearly availabil-
ity of medicines at individual facilities. In addition, the re-
liability of median price ratios is dependent on the number 
of supplier prices used to determine the median interna-
tional reference price of each medicine. In cases where very 
few supplier prices are available, or where there is no sup-
plier price and the buyer price is used as a proxy, median 
price ratio results can be skewed by a particularly high or 
low international reference price. A further limitation is 
that the list of medicines surveyed does not account for the 
availability of alternate strengths or dosage forms, or of 
therapeutic alternatives. Finally, the methodology does not 
include informal sectors, such as markets and general 
stores, as the quality of the medicines found in such sec-
tors cannot be assured.
CONCLUSION
Although further investigation is required to obtain a more 
in–depth understanding of the causes and consequences 
of medicine availability and pricing [28], our findings show 
that several policies are required to make medicines more 
affordable and available in Haiti. First, a comprehensive as-
sessment of the supply chain should be undertaken to 
identify reasons for low availability as well as areas where 
regulation of the procurement chain are appropriate [9,28]. 
Second, a routine assessment of the suppliers and the stor-
age facilities around the country should be undertaken to 
ensure all essential medicines are being stocked and dis-
tributed to dispensing facilities in a timely and efficient 
manner [28].
The government of Haiti could require that its recently ad-
opted National Essential Medicines list be used for purchas-
ing and donation requests by all registered health agencies 
in the public, nonprofit, and mixed sectors as well nonprof-
it and for–profit organizations responsible for production 
and/or importation of medications into Haiti. PROMESS 
could play a key role in these coordination efforts. Restrict-
December 2013  •  Vol. 3 No. 2  • 020405	 8	 www.jogh.org • doi: 10.7189/jogh.03.020405V
I
E
W
P
O
I
N
T
S
P
A
P
E
R
S
Availability, prices and affordability of essential medicines in Haiti
ing acceptance of mass donations to EML medicines after 
disasters is particularly important to avoid the use of dan-
gerous or inappropriate medicines and their associated dis-
posal costs [40]. As a participant in the Pan American 
Health Organization Strategic Fund, Haiti can receive tech-
nical support in procurement planning and programming 
to ensure continuous availability of essential medicines [47]. 
The government and partners should commit to reducing 
the price of the lowest priced generics across all medication 
  1   Laing R, Waning B, Gray A, Ford N. t Hoen E. 25 years of the WHO essential medicines lists: progress and chal-
lenges. Lancet. 2003;361:1723-9. Medline:12767751 doi:10.1016/S0140-6736(03)13375-2
  2   World Health Organization. WHO Definition and Concept of Essential Medicines. Available from: http://www.
who.int/medicines/services/essmedicines_def/en/index.html. Accessed: 5 August 2012.
  3   Anson A, Ramay B, Ruiz de Esparza A, Bero L. Availability, prices and affordability of the World Health Organi-
zation's essential medicines for children in Guatemala. Global Health. 2012;8:22. Medline:22747646 
doi:10.1186/1744-8603-8-22
  4   Cameron A, Ewen M, Ross–Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 de-
veloping and middle–income countries: a secondary analysis. Lancet. 2009;373:240-9. Medline:19042012 
doi:10.1016/S0140-6736(08)61762-6
  5   Cham M, Sundby J, Vangen S. Availability and quality of emergency obstetric care in Gambia's main referral 
hospital: women–users' testimonies. Reprod Health. 2009;6:5. Medline:19366451 doi:10.1186/1742-4755-6-5
  6   Chen W, Tang S, Sun J, Ross–Degnan D, Wagner AK. Availability and use of essential medicines in China: man-
ufacturing, supply, and prescribing in Shandong and Gansu provinces. BMC Health Serv Res. 2010;10:211. 
Medline:20637116 doi:10.1186/1472-6963-10-211
  7   Gitanjali B, Manikandan S. Availability of five essential medicines for children in public health facilities in India: 
A snapshot survey. J Pharmacol Pharmacother. 2011;2:95-9. Medline:21772768 doi:10.4103/0976-500X.81900
  8   Robertson J, Forte G, Trapsida J-M, Hill S. What essential medicines for children are on the shelf? Bull World 
Health Organ. 2009;87:231-7. Medline:19377720 doi:10.2471/BLT.08.053645
R
E
F
E
R
E
N
C
E
S
dispensing sectors in Haiti. Interventions such as removal 
of duties and taxes on essential medicines are an option to 
achieve this goal [27–29,48]. An availability and pricing 
survey should be undertaken every 2 years to allow for con-
tinuous monitoring of impact and efficacy of any new poli-
cies put in place by government and health care partners in 
Haiti. Broad debate and dialogue are needed to identify how 
stakeholders can contribute to enhancing accessibility and 
affordability of essential medicines.
Acknowledgments: Logistical support: Haiti Ministry of Health, Aksyon Inivesite pou Devlopman Di-
rab (AIDD) and University of California Haiti Initiative (UCHI). Advisors: Zoulika Faraj (PAHO); Marg 
Ewen (HAI); Ali Cameron (WHO); data collectors, from UEH: Dorlus Wilson, Mitsy Ulyse, Martine 
Menard, Elyse Gregory, Martin Eddy, Vital Roosevelt, Marx Augustin, Ulysse Samuel, and Philippe Da-
vid; from UCSF: Bill Tan, Denika Shile, Gabe Quitoriano, and Alan Jew; and special thanks to Dr Dorie 
Apollonio and Professor Nancy Hessol for review and tremendously helpful feedback on this manu-
script.
Funding: The study was supported by Pan American Health Organization (PAHO), AmeriCares, Uni-
versity of California, the office of Vice–Chancellor of Student Affairs at University of California, San 
Francisco, and the National Center for Research Resources, the National Center for Advancing Transla-
tional Sciences, and the Office of the Director, National Institutes of Health, through UCSF–Center for 
Translational Sciences Institute Grant Number TL1 RR024129. The contents of the manuscript are sole-
ly the responsibility of the authors and do not necessarily represent the official views of the NIH. The 
funders had no role in the study design, data collection and analysis, decision to publish, or prepara-
tion of the manuscript.
Authorship declaration: HC designed project protocol, managed project, supervised and collected 
data; performed data analysis, produced initial manuscript; NSF assisted in protocol design and project 
management, supervised and collected data, provided input on manuscript, LB designed project pro-
tocol, supervised project, assisted in data analysis, assisted in writing manuscript.
Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.
org/coi_disclosure.pdf (available on request from the corresponding author). IR declares support from 
UNICEF for the submitted work. The authors declare no financial relationships with any organizations 
that might have an interest in the submitted work in the previous 3 years; and no other relationships 
or activities that could appear to have influenced the submitted work.
www.jogh.org • doi: 10.7189/jogh.03.020405	 9	 December 2013  •  Vol. 3 No. 2  • 020405V
I
E
W
P
O
I
N
T
S
P
A
P
E
R
S
Chahal et al.
R
E
F
E
R
E
N
C
E
S
  9   Ridge AL, Bero LA, Hill SR. Identifying barriers to the availability and use of Magnesium Sulphate Injection in 
resource poor countries: a case study in Zambia. BMC Health Serv Res. 2010;10:340. Medline:21162717 
doi:10.1186/1472-6963-10-340
10   Partners In Health. Haiti Profile. Available from: http://www.pih.org/. Accessed: 5 August 2013.
11   The World Bank. GDP per Capita (Current USD). The World Bank. Available from: http://data.worldbank.org/
indicator/NY.GDP .PCAP .CD. Accessed: 15 March 2013.
12   The World Bank. Haiti Profile. 2013. Available from: http://www.worldbank.org/en/country/haiti. Accessed: 15 
March 2013
13   World Health Organization. Haiti profile. Available from: http://www.who.int/countries/hti/en/. Accessed: 13 
October 2012.
14   UNICEF . Levels and Trends in Child Mortality, 2012. Available from: http://www.childmortality.org/files_v9/
download/Levels%20and%20Trends%20in%20Child%20Mortality%20Report%202012.pdf. Accessed: 13 Oc-
tober 2012.
15   World Health Organization. WHO World Health Statistics 2007 – TB prevalence in Haiti in 2005. Available 
from: www.who.int/whosis/whostat2007/en/index.html. Accessed: 5 August 2012.
16   Pan American Health Organization. Health in the Americas – Regional Outlook and Country Profiles Washing-
ton, D.C.: Pan American Health Organization; 2012. Available from: http://www.paho.org/saludenlasamericas/
index.php?option=com_content&view=article&id=9&Itemid=14&lang=en. Accessed: 12 June 2013.
17   UNICEF . Committing to Child Survival: A Promise Renewed 2012. Available from: http://www.unicef.org/vid-
eoaudio/PDFs/APR_Progress_Report_2012_final.pdf. Accessed: 14 June 2013.
18   PROMESS. Essential Medicines Program. Available from: http://new.paho.org/hai/index.php?option=com_cont
ent&view=article&id=7006&Itemid=232&lang=en. Accessed: 14 June 2012.
19   Health Action International (HAI) and World Health Organization. Medicine prices, availability, affordability 
and price components, 2nd edition, 2009. Available from: http://www.haiweb.org/medicineprices/manual/doc-
uments.html. Accessed: 1 August 2011.
20   Health Action International. WHO Global and Regional Core Medicines Lists. Available from: http://www.hai-
web.org/medicineprices/manual/documents.html. Accessed: 1 August 2012.
21   World Health Organization. Better Medicines for Children Project. Available from: http://www.who.int/child-
medicines/en/. Accessed: 2 March 2012.
22   Government of Haiti. Medicaments Essentiels. Available from: http://www.who.int/selection_medicines/coun-
try_lists/hti/en/index.html. Accessed: 5 August 2012.
23   OANDA. Forex Trading and Exchange Rates Services | OANDA [updated 2011/08/04/]. Available from: http://
www.oanda.com/. Accessed: 4 August 2011.
24   Management Sciences for Health. ERC – International Drug Price Indicator Guide 2010. Available from: http://
erc.msh.org/mainpage.cfm?file=1.0.htm&&module=DMP&language=English. Accessed: 1 June 2011.
25   Government of Haiti. Ministere de l’Economie et des Finances, Institut Haitien de Statistique et d’Informatique. 
Available from: http://www.ihsi.ht/rgph_resultat_ensemble_CE.htm#. Accessed: 5 August 2012.
26   Cameron A, Roubos I, Ewen M, Mantel–Teeuwisse AK, Leufkens HGM, Laing RO. Differences in the availabil-
ity of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull 
World Health Organ. 2011;89:412-21. Medline:21673857 doi:10.2471/BLT.10.084327
27   Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, et al. The availability and affordability of se-
lected essential medicines for chronic diseases in six low– and middle–income countries. Bull World Health Or-
gan. 2007;85:279-88. Medline:17546309 doi:10.2471/BLT.06.033647
28   van Mourik MS, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: 
a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord. 2010;10:25. Medline:20534118 
doi:10.1186/1471-2261-10-25
29   Kotwani A, Ewen M, Dey D, Iyer S, Lakshmi PK, Patel A, et al. Prices & availability of common medicines at six 
sites in India using a standard methodology. Indian J Med Res. 2007;125:645-54. Medline:17642500
30   Seya M-J, Gelders SFAM, Achara OU, Milani B, Scholten WK. A first comparison between the consumption of 
and the need for opioid analgesics at country, regional, and global levels. J Pain Palliat Care Pharmacother. 
2011;25:6-18. Medline:21426212 doi:10.3109/15360288.2010.536307
31   Guetti C, Angeletti C, Paladini A, Varrassi G, Marinangeli F . Pain and Natural Disaster. Pain Pract. 2012; Epub 
ahead of print. Medline:23241164 doi:10.1111/papr.12010
32   De Lima L, Bruera E, Joranson DE, Vanegas G, Cepeda S, Quesada L, et al. Opioid availability in Latin America: 
the Santo Domingo report progress since the Declaration of Florianopolis. J Pain Symptom Manage. 1997;13:213-
9. Medline:9136232 doi:10.1016/S0885-3924(96)00325-9
33   De Lima L, Sweeney C, Palmer JL, Bruera E. Potent analgesics are more expensive for patients in developing 
countries: a comparative study. J Pain Palliat Care Pharmacother. 2004;18:59-70. Medline:15148009
34   World Health Organization. WHO Global status report on noncommunicable diseases, 2010. Available from: 
http://www.who.int/nmh/publications/ncd_report2010/en/. Accessed: 5 August 2012.
35   Niëns LM, Cameron A, Van de Poel E, Ewen M, Brouwer WBF , Laing R. Quantifying the impoverishing effects 
of purchasing medicines: a cross–country comparison of the affordability of medicines in the developing world. 
PLoS Med. 2010;7:e1000333. Medline:20824175 doi:10.1371/journal.pmed.1000333
December 2013  •  Vol. 3 No. 2  • 020405	 10	 www.jogh.org • doi: 10.7189/jogh.03.020405V
I
E
W
P
O
I
N
T
S
P
A
P
E
R
S
Availability, prices and affordability of essential medicines in Haiti
36   van Doorslaer E, O'Donnell O, Rannan–Eliya RP , Somanathan A, Adhikari SR, Garg CC, et al. Effect of payments 
for health care on poverty estimates in 11 countries in Asia: an analysis of household survey data. Lancet. 
2006;368:1357-64. Medline:17046468 doi:10.1016/S0140-6736(06)69560-3
37   Strand TA, Chandyo RK, Bahl R, Sharma PR, Adhikari RK, Bhandari N, et al. Effectiveness and efficacy of zinc 
for the treatment of acute diarrhea in young children. Pediatrics. 2002;109:898-903. Medline:11986453 
doi:10.1542/peds.109.5.898
38   UNICEF . Children in Haiti – One Year After – The Long Road from Relief to Recovery 2011. Available from: 
http://www.unicef.org/media/. Accessed: 5 August 2012.
39   Pan American Health Organization. Earthquake in Haiti – One Year Later Washington, D.C.: PAHO; 2011. Avail-
able from: http://www.paho.org/disasters/index.php?option=com_content&task=view&id=1088&Itemid=904
. Accessed: 14 June 2013.
40   Bero L, Carson B, Moller H, Hill S. To give is better than to receive: compliance with WHO guidelines for drug 
donations during 2000–2008. Bull World Health Organ. 2010;88:922-9. Medline:21124717 doi:10.2471/
BLT.10.079764
41   World Health Organization. WHO Guidelines for Medicine Donations, 2010. Available from: http://www.who.
int/medicines/publications/med_donationsguide2011/en/index.html. Accessed: 5 August 2012.
42   de Ville de Goyet C, del Cid E, Romero A, Jeanne E, Lechat M. Earthquake in Guatemala: epidemiologic evalu-
ation of the relief effort. Bull Pan Am Health Organ. 1976;10:95-109. Medline:974305
43   Fernandopull R, Benaragam B. The Expectations, the Reality and the Burden of Drug Donations. 2007. Avail-
able from: http://apps.who.int/medicinedocs/documents/s17523en/s17523en.pdf. Accessed: 5 August 2012.
44   Frontieres PS. (PSF). Study on Drug Donations in the Province of Aceh in Indonesia. Available from: http://www.
acfid.asn.au/what–we–do/docs_what–we–do/. Accessed: 5 August 2012.
45   Pan American Health Organization. A Practical Guide For Procurement Planning And Management Of Strategic 
Public Health Supplies Washington, D.C.: PAHO; 2006. Available from: http://apps.who.int/medicinedocs/en/m/
abstract/Js19024en/. Accessed: 14 June 2013.
46   Madden JM, Meza E, Ewen M, Laing RO, Stephens P , Ross–Degnan D. Measuring medicine prices in Peru: val-
idation of key aspects of WHO/HAI survey methodology. Rev Panam Salud Publica. 2010;27:291-9. Med-
line:20512232 doi:10.1590/S1020-49892010000400008
47   Pan American Health Organization. PAHO Structure and Participation – Participating Countries 2013. Available 
from: http://new.paho.org/hq/index.php?option=com_content&view=article&id=1045&Itemid=987&lang=en
&limitstart=4. Accessed: 22 March 2013.
48   Olcay M, Laing R. Pharmaceutical Tariffs: What is their effect on prices, protection of local industry and revenue 
generation? The Commission on Intellectual Property Rights, Innovation and Public Health; 2005. Available 
from: http://www.who.int/intellectualproperty/studies/tariffs/en/index.html. Accessed: 5 August 2012.
R
E
F
E
R
E
N
C
E
S
www.jogh.org • doi: 10.7189/jogh.03.020405	 11	 December 2013  •  Vol. 3 No. 2  • 020405